GlaxoSmithKline: EU body backs ViiV's new HIV treatment
(CercleFinance.com) - European regulators on Friday issued a positive opinion for a treatment of HIV infection which is expected to be the smallest single-pill regimen in the market.
GSK's ViiV Healthcare said that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Juluca for the treatment of HIV infection in virologically suppressed adults.
The single-pill, two-drug regimen would enable patients to reduce the number of drugs needed to treat HIV in those who are virologically suppressed, the company said.
The two-drug regimen comprises ViiV's dolutegravir and Janssen's rilpivirine.
For the record, ViiV Healthcare is majority-owned by GlaxoSmithKline, with Pfizer and Shionogi as other shareholders.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
GSK's ViiV Healthcare said that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Juluca for the treatment of HIV infection in virologically suppressed adults.
The single-pill, two-drug regimen would enable patients to reduce the number of drugs needed to treat HIV in those who are virologically suppressed, the company said.
The two-drug regimen comprises ViiV's dolutegravir and Janssen's rilpivirine.
For the record, ViiV Healthcare is majority-owned by GlaxoSmithKline, with Pfizer and Shionogi as other shareholders.
Copyright (c) 2018 CercleFinance.com. All rights reserved.